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Clinical, Biochemical, and 
Biophysical Markers of 
Angiogenesis in Preeclampsia
Osredkar Joško and Kumer Kristina
Abstract
Preeclampsia/eclampsia is described as a pregnancy-specific systemic disorder 
of unknown etiology and is a potentially life-threatening disease with symp-
toms related to a general vascular endothelial cell activation and dysfunction. 
Preeclampsia can be defined as a new onset of hypertension (>140/90 mmHg) 
after gestational week 20 together with significant proteinuria (300 mg/24 h). 
Preeclampsia has a complex pathophysiology, the primary cause likely being abnor-
mal placentation. Angiogenic factors and biophysical markers may be combined for 
predicting preeclampsia. Various high-throughput techniques have evolved, thus 
allowing us simultaneous examination of thousands of genes (genomics), gene 
transcripts (transcriptomics), proteins (proteomics), metabolites (metabolomics), 
protein interaction (interactomics), and chromatin modifications (epigenomics) in 
single experiments, and the results suggest that the use of transcriptomic, pro-
teomic, and metabolomic profiles may be predictive for preeclampsia.
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1. Classification and epidemiology of hypertension during pregnancy
Hypertension is the second most prevalent maternal complication worldwide 
after anemia in pregnancy, and it is associated with a significant morbidity and 
mortality of the mother and fetus. The American College of Obstetricians and 
Gynecologists Task Force on Hypertension in Pregnancy has modified the older clas-
sification of hypertension during pregnancy in only four categories: (1) preeclamp-
sia-eclampsia, (2) chronic hypertension (of any cause), (3) chronic hypertension 
with superimposed preeclampsia, and (4) gestational hypertension (Figure 1). It has 
been suggested that an older category, “unclassified,” be reintroduced or replaced by 
“suspected” or “presumptive” preeclampsia [1].
In 2017, the American College of Cardiology and American Heart Association 
(ACC/AHA) issued a clinical practice guideline on hypertension that reclas-
sified the previous category of prehypertension into elevated BP (systolic BP 
120–129 mmHg) and stage 1 hypertension (systolic BP 130–139 mmHg or diastolic 
BP 80–89 mmHg) [2]. However a rise of diastolic blood pressure over prepregnant 
levels (delta hypertension) rather than a rise above absolute value is also a signifi-
cant predictive marker.
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2. Definition of preeclampsia
Preeclampsia/eclampsia is described as a pregnancy-specific systemic disorder 
of unknown etiology and is a potentially serious disease with symptoms related to 
a generalized vascular endothelial activation. The placenta seems to be a crucial 
component in the pathophysiology of the disease. Preeclampsia is a multisystemic 
disease characterized by the development of hypertension after 20 weeks of 
gestation, with the presence of proteinuria or, in its absence, of signs or symptoms 
indicative of target organ injury [3, 4].
Preeclampsia can be defined as a new onset of hypertension (>140/90 mmHg) 
after gestational week 20 together with significant proteinuria (300 mg/24 h) 
[5, 6]. Hypertension is considered mild until diastolic or systolic levels reach or 
exceed 110 and 160 mmHg, respectively. It is recommended that a diagnosis of 
hypertension requires at least two determinations at least 4 h apart. Proteinuria 
is diagnosed when 24-h excretion equals or exceeds 300 mg in 24 h or the ratio 
of measured protein to creatinine in a single-voided urine measures or exceeds 
0.3 (each measured as mg/dL), termed the urinary protein/creatinine ratio [1]. 
The definitive treatment of preeclampsia is delivery to prevent development of 
Figure 1. 
Classification of hypertensive disorders in pregnancy.
Severe features of preeclampsia (any of these findings):
A. Systolic blood pressure of 160 mmHg or higher or diastolic blood pressure of 110 mmHg or 
higher on two occasions at least 4 h apart
B. Thrombocytopenia
C. Impaired liver function as indicated by abnormally elevated liver enzymes
D. Progressive renal insufficiency
E. Pulmonary edema
F. New-onset cerebral or visual disturbances
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maternal or fetal complications from disease progression. Timing of delivery is 
based upon gestational age, the severity of preeclampsia, and maternal and fetal 
condition.
3. Key elements of the pathophysiology
Precise causes of preeclampsia are still unknown, but contributors are impaired 
angiogenesis [7], systemic endothelial dysfunction [8], and decreased vascular 
compliance resulting in impaired accommodation of the volume expansion required 
for healthy gestation [9].
During normal pregnancy, the villous cytotrophoblast invades into the inner 
third of the myometrium, and spiral arteries are remodeled. The remodeling 
contains four steps: decidua-associated remodeling, the intraluminal appearance 
of migratory endovascular trophoblasts, their intramural incorporation and 
trophoblast-associated remodeling, and maternal reendothelialization.
Preeclampsia has a complex pathophysiology, the primary cause likely being 
abnormal placentation. Defective invasion of the spiral arteries by cytotrophoblast 
cells is observed during preeclampsia. Recent studies have shown that cytotropho-
blast invasion of the uterus is actually a unique differentiation pathway in which 
the fetal cells adopt certain attributes of the maternal endothelium they normally 
replace. In preeclampsia, this differentiation process is defective [10].
In normal pregnancy the uterine arteries are resilient and elastic, and they lose their 
sensitivity to vasoconstrictors. In a preeclamptic pregnancy there is increased uterine 
arterial resistance and higher sensitivity to vasoconstrictors and thus chronic placental 
ischemia and oxidative stress. This chronic placental ischemia causes fetal complica-
tions, including fetal growth restriction (FGR) and intrauterine death. In parallel, 
oxidative stress induces release into the maternal circulation of substances such as free 
radicals, oxidized lipids, cytokines, and serum soluble vascular endothelial growth fac-
tor receptor 1 (sVEGFR-1/sFlt-1). These abnormalities are responsible for endothelial 
dysfunction [8] with vascular hyperpermeability, thrombophilia, and hypertension, so 
as to compensate for the decreased blood flow in the uterine arteries due to peripheral 
vasoconstriction. Endothelial dysfunction is responsible for the clinical signs observed 
in the mother, i.e., impairment of the hepatic endothelium contributing to onset of 
the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, 
impairment of the cerebral endothelium inducing cerebral edema or posterior 
Figure 2. 
Pathogenesis of preeclampsia.
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reversible encephalopathy syndrome (PRES), refractory neurological disorders, or 
even eclampsia. In kidney, the depletion of vascular endothelial growth factor (VEGF) 
in the podocytes leads to endotheliosis, and these block the slit diaphragms in the base-
ment membrane, exacerbating the already decreased glomerular filtration and causing 
proteinuria. Finally, endothelial dysfunction promotes microangiopathic hemolytic 
anemia, and vascular hyperpermeability associated with low serum albumin causes 
edema, particularly in the lower limbs or lungs. The crucial issue to understand is that 
the prime mover of preeclampsia is abnormal placentation [11] [Figure 2].
4. Symptoms
Preeclampsia sometimes develops without any symptoms. High blood pressure 
may develop slowly, or it may have a sudden onset. Monitoring of blood pressure 
is an important part of prenatal care because the first sign of preeclampsia is 
commonly a rise in blood pressure. Blood pressure that exceeds 140/90 mmHg—
documented on two occasions, at least 4 h apart—is considered abnormal.
Other signs and symptoms of preeclampsia may include:
• Excess protein in urine (proteinuria)
• Severe headaches
• Vision changes include sensations of flashing lights, light sensitivity,  
blurry vision, or spots
• Upper abdominal pain, usually under ribs on the right side
• Nausea or vomiting
• Decreased urine output
• Decreased levels of platelets in the blood (thrombocytopenia)
• Impaired liver function
• Shortness of breath and anxiety
• Sudden weight gain
• Swelling (edema)
Many of these symptoms also occur in normal pregnancies, so they are not 
considered reliable signs of preeclampsia though they will alert the obstetrician.
The International Society of Study of Hypertension in Pregnancy (ISSHP) 
recently suggested that a clinical diagnosis is made even in the absence of 
proteinuria if organ-specific signs or symptoms are present with new onset of 
hypertension [12].
Hemolysis, abnormal elevation of liver enzymes levels, and low platelet count 
occur together as the HELLP syndrome [13]. HELLP syndrome is a severe variant 
of preeclampsia that occurs in 5% of cases and can progress rapidly to a life- 
threatening condition [14]. The presence of seizures in preeclampsia is eclampsia 
and is another complication during pregnancy and at delivery. In Table 1, diagnos-
tic criteria are summarized.
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5. Risk factors of preeclampsia
Risk factors include health conditions, lifestyle, and family history that can 
increase the risk for high blood pressure.
Some of the risk factors for high blood pressure cannot be controlled, such as age 
or family history. But we can take steps to lower our risk by changing the factors we 
can control.
Some medical conditions can raise the risk for high blood pressure. If one of 
these risks is present, the pregnant women can take steps to control it and lower the 
risk. However preeclampsia cannot be prevented, but the complications of pre-
eclampsia can be prevented.
Blood pressure
• Greater than or equal to 140 mm Hg systolic or greater than or equal to 90 mm Hg diastolic on two 
occasions at least 4 h apart after 20 weeks of gestation in a woman with a previously normal blood pressure
• Greater than or equal to 160 mm Hg systolic or greater than or equal to 110 mm Hg diastolic; hypertension 
can be confirmed within a short interval (minutes) to facilitate timely antihypertensive therapy
and
Proteinuria
• Greater than or equal to 300 mg per 24 h urine collection (or this amount extrapolated from a timed 
collection)
or
• Protein/creatinine ratio greater than or equal to 0.3*
• Dipstick reading of 1+ (used only if other quantitative methods not available)
Or in the absence of proteinuria, new-onset hypertension with the new onset of any of the following:
Thrombocytopenia
• Platelet count less than 100,000/μl
Renal insufficiency
• Serum creatinine concentrations greater than 1.1 mg/dL or a doubling of the serum creatinine concentration 
(normal levels in pregnancy are 0.8 mg/dL) in the absence of other renal disease
Impaired liver function
• Elevated blood concentrations of liver transaminases to twice normal concentration
Pulmonary edema
Cerebral or visual symptoms
*Each measured as mg/dL.
Table 1. 
Diagnostic criteria for preeclampsia by ACOG.
ACOG recommendation, any risk factor [1] NICE guidelines, one high risk or two moderate risk factors 
[15]
Risk factors High risk factors
Nulliparity Hypertensive disease in previous pregnancy
Age > 40 years Chronic kidney disease
BMI > 30 kg/m2 Diabetes mellitus
Family history of PE Chronic hypertension
History of previous pregnancy with PE Autoimmune disease
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Preeclampsia develops only as a complication of pregnancy. Risk factors are 
presented in Table 2 together with data of increased risk for some items [15].
The National Institute for Health and Care Excellence (NICE) recommends that 
women with high and more than one of the moderate risk factors for preeclampsia 
should be advised to take aspirin from 12 weeks gestation [16].
6. Biochemical markers
The role of biomarkers in preeclampsia diagnosis is becoming increasingly 
important. A literature review gives us a range of biomarkers that have proved to be 
sufficiently specific and sensitive to be classified as potential biomarkers (Figure 3). 
The most researched with data on specificity and sensitivity are given in Table 3. A 
good biomarker would be one, which may have the potential of identifying women 
earlier in their disease course. There have been also many studies investigating 
multiple-marker algorithms for predicting preeclampsia.
Figure 3. 
Biochemical markers in preeclampsia. sFlt-1, soluble fms-like tyrosine kinase 1; PlGF, placental growth factor; 
sEng, soluble endoglin; PP13, placental protein 13; PAPP-A, pregnancy-associated plasma protein A.
ACOG recommendation, any risk factor [1] NICE guidelines, one high risk or two moderate risk factors 
[15]
Conception by in vitro fertilization
Chronic hypertension Moderate risk factors
Chronic renal disease Nulliparity
Diabetes mellitus Age > 40 years
Systemic lupus erythematosus Interpregnancy interval > 10 years
Thrombophilia BMI at first visit > 35 kg/m2
Chronic hypertension
ACOG, American College of Obstetricians and Gynecologists; NICE, National Institute of Clinical Excellence; PE, 
preeclampsia
Table 2. 
Risk factors for preeclampsia by ACOG and NICE recommendations.
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6.1 Soluble fms-like tyrosine kinase 1 (sFlt-1)
Soluble Flt-1 is an anti-angiogenic form of VEGF receptor 1. sFlt-1 acts as a 
potent scavenger of VEGF and PlGF (Figure 4), thus preventing their interaction 
with endothelial receptors on the cell surface, and subsequently induces endothelial 
dysfunction. Elevated concentration of sFlt-1 has been as early as 5 weeks before the 
diagnosis of preeclampsia and correlates with severity of disease [17, 18]. Some other 
studies also support this sFlt-1 role in the pathogenesis of preeclampsia [19–21].
6.2 Placental growth factor
Placental growth factor (PlGF) is a prominent angiogenic factor in the develop-
ment of the placental vascular system [22, 23]. During normal pregnancy, PlGF can 
Biomarker Sensitivity Specificity
sFlt-1 26–73.1% 88.5–100%
PlGF 64.1% 89.5%
sFlt-1/ PlGF 78% 84%
sEng 18–85% 69–84.6%
PP13 79–100% 80–90%
PAPP-A 1st trimester 49.7–69.7% 68.6–85.7%
NGAL 97.89% 93.55%
Insulin resistance 73% 85%
SHBG 85% 37.7%
Inhibin A and activin A 87% 80%
Copeptin 1st trimester 88% 81%
Uterine artery Doppler Positive likelihood ratio 9:1
Podocytes 38–100% 70–100%
sFlT-1, soluble fms-like tyrosine kinase 1; NGAL, neutrophil gelatinase-associated lipocalin; PAPP, pregnancy-
associated plasma protein; PP, placental protein; sEng, soluble endoglin; SHBG, sex hormone-binding globulin
Table 3. 
Biomarker test characteristics for prediction.
Figure 4. 
Circulating sFlt-1 in the maternal blood leads to a net decrease in PlGF and VEGF in the vasculature, which 
are necessary for normal placental angiogenesis. In PE angiogenic balance is disturbed and may result in 
endothelial dysfunction.
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be detected in the maternal circulation from 8 weeks gestation, reaching a maximal 
concentration toward the end of second trimester and declining thereafter until 
delivery [24]. In line with its pro-angiogenic function, reduced levels of PlGF were 
found in preeclampsia [18, 25, 26].
The commercial kits available for determination of PlGF are mostly using 
sandwich enzyme-linked immunosorbent assay (ELISA) (Roche Diagnostics 
International, Thermo Fisher Scientific, IBL International, Abcam) or fluo-
roimmunometricassay (PerkinElmer). In a multicenter, prospective study 
PROGNOSIS the Elecsys (Roche) sFlt-1/PlGF ratio proved to be a helpful tool 
in enabling clinicians to rule out the occurrence of preeclampsia for 1 week at 
cutoff of 38 or lower in women in whom the syndrome is suspected clinically. A 
ratio more than 38 indicates an increased risk of developing preeclampsia in the 
next 4 weeks [27].
6.3 sEndoglin
Endoglin (Eng) is a type I membrane glycoprotein localized to the cell mem-
brane where it constitutes the transmembrane co-receptor for TGF beta receptor 
complex (TGF-β1 and TGF-β3) [28]. Circulating sEng was found to be high in pre-
eclamptic women even prior to the disease manifestations correlating with disease 
severity and falls after delivery [17, 29], making it a reliable predictor of patients 
destined to develop severe early-onset preeclampsia [30].
Research has shown that near the time of delivery there is a rise in anti- 
angiogenic factors including [31, 32] soluble endoglin (sEng) [33], a drop in the 
pro-angiogenic placental growth factor (PlGF) [17], and slight changes in the 
vascular endothelial growth factor (VEGF) [34]. These have been associated with 
increases in the anti-angiogenic sFlt-1/PlGF ratio [35] and a decrease in the pro-
angiogenic PlGF/(sFlt-1 + sEng) ratio [36, 37].
Other studies have reported increases in inhibin A [38] and placental protein 
13 (PP13) [39] near delivery. The elevated tumor necrosis factor alpha (TNFα) has 
been detected in preterm delivery [40] and also in FGR [41].
6.4 Placental protein 13 (PP13)
PP13 is a member of the galectin family, predominantly expressed by the 
syncytiotrophoblast, during placental vascular development [42, 43]. Serum 
concentrations of PP13 are significantly lower in women who later develop pre-
eclampsia, FGR, and preterm birth [39, 44]. Combining first trimester PP13 with 
other parameters may further improve predictive performance.
6.5 Pregnancy-associated plasma protein A (PAPP-A)
PAPP-A is a peptidase produced by syncytiotrophoblast with hydrolytic activity 
for insulin-like growth factor-binding proteins [45, 46]. Decreased levels of PAPP-A 
in the first trimester have been associated with increased risk of preeclampsia [47], 
not a good predictor of late-onset preeclampsia [48].
6.6 Free fetal nucleic acids
The examination of fetal cells, specifically erythroblasts, and of cell-free fetal 
DNA from the blood of pregnant women is a subject of intense research, with 
the aim of developing new risk-free methods for prenatal diagnosis [49, 50]. In 
preeclamptic pregnancies [51], cell-free fetal DNA is elevated long before the 
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clinical onset of the disease [52, 53]. Total free DNA has also been used and has been 
reported to be increased in women who subsequently develop preeclampsia [54].
New methods based on immunodiagnostics that measure the level of biomark-
ers as well as sonographic devices that measure the uterine artery blood flow have 
emerged as promising avenues that can lead to more accurate differential diagnoses.
6.7 Biophysical markers
Biophysical markers have also been developed to evaluate blood flow through the 
uterine arteries to the placenta. In the case of preeclampsia, an abnormal placenta-
tion results in decreased penetration of maternal spiral arteries in the junctional 
zone myometrium by cytotrophoblast cells. The consequence is that high blood 
flow and low-resistance vessels do not occur. Doppler ultrasonography has been 
evaluated as a potential predictive test for preeclampsia. Parameters such as the 
resistance index to the flow (RI), the average pulsatility index (PI), and the peak 
systolic flow (PSF) have been identified [55–58, 76].
6.8 Combination of tests
Angiogenic factors and biophysical markers may be combined for predicting 
preeclampsia. The combinations which give us best results are biochemical markers 
sFlt-1 and PlGF with Doppler [59, 60] and additional sEng [36] or PP13 [36, 61–63] 
and PAPP-A [63–66]. The pooled sensitivity of all single biomarkers for PE was 0.40 
(95% Cl 0.39–0.41) at a false-positive rate of 10%. The area under the summary of 
receiver operating characteristic curve (SROC) was 0.786. The pooled sensitivity 
and specificity of the separate meta-analyses for some biomarkers are shown in 
Table 4. Wu et al. in their study got a pooled sensitivity of 0.91 (95% Cl: 0.90–0.91) 
and SROC of 0.893 for a combination of clinical characteristics, biomarkers, and 
Doppler pulsatility indexes [67].
7. Novel methods of diagnosis
Nowadays, various high-throughput techniques have evolved, thus allowing us 
simultaneous examination of thousands of genes (genomics), gene transcripts (tran-
scriptomics), proteins (proteomics), metabolites (metabolomics), protein interaction 
(interactomics), and chromatin modifications (epigenomics) in single experiments.
mRNA-circulating placenta-specific mRNA in serum from preeclamptic 
women might be useful for the prediction of preeclampsia. In this study inhibin A, 
Biomarker The characteristics for prediction (95% Cl)
PAPP-A Sensitivity 0.30 (0.29–0.32)
Specificity 0.92 (0.92–0.92)
Inhibin A Sensitivity 0.32 (0.25–0.39)
Specificity 0.90 (0.89–0.91)
PP13 Sensitivity 0.37 (0.33–0.41)
Specificity 0.88 (0.87–0.89)
PlGF Sensitivity 0.65 (0.63–0.67)
Specificity 0.89 (0.89–0.89)
Table 4. 
The pooled sensitivity and specificity of the separate meta-analyses for some biomarkers.
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p-selectin, and VEGF receptor mRNA values were higher in preeclampsia, 
whereas human placental lactogen, KISS-1, and plasminogen activator type 1 
were lower, both compared to normotensive controls [68]. Similar results were 
reported from some other studies also [69, 70], where circulating cells of fetal/
placental origin were a source of mRNA. mRNAs were increased in women with 
preeclampsia, and there was a direct correlation between expression levels and 
the severity of the disease.
Protein, a functional product of gene expression can be measured. A set of 
differently expressed proteins which are involved in lipid metabolism, coagula-
tion, complement regulation, extracellular matrix remodeling, protease inhibi-
tor activity, and acute phase responses can be measured. A different pattern of 
proteins between the group of women who subsequently developed preeclampsia 
on one side and without preeclampsia on the other side [71] was reported. It is 
also reported that women with severe preeclampsia have a unique urine proteomic 
pattern [72] and that this proteomic profile appeared more than 10 weeks before 
the clinical manifestations, and this distinguished preeclampsia from other hyper-
tensive or proteinuric disorders in pregnancy [73].
Some studies revealed that metabolomic strategies might be appropriate for 
investigating the metabolic function of trophoblast or placental tissue, and it was 
found that preeclamptic pregnancies have a different metabolomic profile when 
compared to normal pregnancies [74, 75].
These novel technologies in preeclampsia appear quite promising. The num-
ber of studies is growing, and the results suggest that the use of transcriptomic, 
proteomic, and metabolomic profiles may be predictive for preeclampsia. These 
techniques open new possibilities to find a new set of biomarkers for preeclampsia. 
Future studies are needed, with the collaborative efforts of bioinformatics, biosta-
tistics, researchers, and clinicians.
8. Conclusions
Many studies demonstrate the importance of optimal management of blood 
pressure in pregnancy hypertension. The use of angiogenic biomarkers gives us 
promising results for the prediction and diagnosis of preeclampsia, but there is still 
a lack of specific and reliable biomarkers to predict preeclampsia, particularly in 
the first trimester of pregnancy. New methods to isolate and characterize markers 
outside the protein field (lipids, nucleic acids, etc.) from serum/plasma/urine/
saliva are useful.
Key points
A. Preeclampsia is a pregnancy-specific hypertensive disorder with or without proteinuria that occurs 
after 20 weeks of gestation in a previously normotensive woman. In the absence of proteinuria, 
the diagnosis can still be made if new-onset hypertension is accompanied by signs or symptoms of 
significant end-organ dysfunction.
B. Major risk factors for development of preeclampsia include past history of preeclampsia, pregesta-
tional diabetes, chronic hypertension, and autoimmune disease.
C. The pathologic changes are present long before clinical manifestations.
D. Endothelial dysfunction and disturbed angiogenic balance are one of the key features of the 
disease.
E. Preeclampsia serum levels of VEGF, PLGF, PP13, and inhibin A are decreased, and sFlt-1 and sEng 
are increased.
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